Pain Management in Osteoarthritis through Homoeopathy
- Conditions
- Health Condition 1: null- Osteoarthritis
- Registration Number
- CTRI/2014/02/004372
- Lead Sponsor
- Central Council for Research in Homoeopathy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Patients above the age of 50 years, presenting with knee pain and evidence of osteophytes in the knee radiograph
•Rheumatoid factor more than 1:40 titre
•ESR more than 40mm/hour
•Serum uric acid level >7 mg/dL in men or >6 mg/dL in women
•Severe degeneration of knee joint with marked joint narrowing, varus, or valgus deformity of knee ( > 12°); evidenced by imaging or other evidences and requiring surgical intervention
•Non-ambulant patients
•Self-reported joint disorders (e.g. inflammatory joint disease, specific arthropathy, severe axis deviations or instabilities, joint or skin infections, joint prostheses of the lower limbs) other than OA
•IA injections within 2 weeks prior to study entry
•Cases with other systemic unevaluated or uncontrolled diseases like diabetes mellitus, hypertension, or other cardiovascular, renal, gastro-intestinal, endocrinal, gynecological diseases etc. or systemic infections affecting quality of life or on other treatment therapies
•Psychiatric illness
•Patients with any vital organ failure
•Recent knee surgery within last 6 months
•Cases with transplanted knees
•History of homeopathic treatment for any chronic disease within last 6 months
•Self-reported immune-compromised states
•Alcohol and/or drug addiction or dependence
•Cases with controlled/uncomplicated hypertension, diabetes mellitus, etc. will not be excluded. Patients on life-saving conventional drug therapies, e.g. anti-diabetics, anti-hypertensives, thyroid drugs etc. for co-morbidities under control, will be continued.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in pain, stiffness, limitation of movement on an identified scale <br/ ><br>Change in pain measured on identified scale (OARSI - OMERACT constant/intermittent pain measure)Timepoint: every 15 days till 2 months of treatment
- Secondary Outcome Measures
Name Time Method Change in requirement of NSAIDs during the course of treatment <br/ ><br>â?¢Incidence of any adverse events/severe adverse events during the period of treatmentTimepoint: every 15 days till 2 months of treatment